During Trastuzumab Therapy, Many Patients May Have Suboptimal Cardiac Monitoring

Share this content:

the Cancer Therapy Advisor take:

A large proportion of patients treated with adjuvant trastuzumab had suboptimal cardiac monitoring, a recent study published in the Journal of Clinical Oncology has shown.

For the study, researchers sought to investigate the patterns of cardiac monitoring and identify factors associated with adequate monitoring among older patients with breast cancer treated with adjuvant trastuzumab. Researchers identified 2,203 patients with a median age of 72 years will full Medicare coverage, diagnosed with stage I-III breast cancer, and treated with trastuzumab-based chemotherapy.

Results showed that only 36.0% of patients were adequately monitored for cardiac toxicity. Researchers found that a more recent year of diagnosis (HR = 1.83; 95% CI: 1.32-2.54), anthracycline use (HR = 1.39; 95% CI: 1.14-1.71), female prescribing physician (HR = 1.37; 95% CI: 1.10-1.70, and physician graduating after 1990 (HR = 1.66; 95% CI: 1.29-2.12) were associated with optimal cardiac monitoring.

The findings suggest that efforts to improve the adequacy of cardiac monitoring during adjuvant trastuzumab treatment are needed, especially in patients at higher risk for cardiotoxicity.

Masitinib plus gemcitabine may be effective in the treatment of specific subgroups of patients with
A large proportion of breast cancer patients treated with adjuvant trastuzumab had suboptimal cardiac monitoring.
Patients treated with adjuvant trastuzumab require adequate cardiac monitoring. We describe the patterns of cardiac monitoring and evaluate factors associated with adequate monitoring in a large population-based study of older patients with breast cancer.
READ FULL ARTICLE From Ascopubs

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters